Doxazosin attenuates renal matrix remodeling mediated by anti-α1-adrenergic receptor antibody in a rat model of diabetes mellitus

Zhao, Lei; Lin, Yanyan; Liu, Yi; Xu, Chunyan; Liu, Ye; Bai, Weiwei; Tan, Xueying; Li, Dezhong; Xu, Jingyu

doi:10.3892/etm.2017.4827

Cited by 4 publications

(4 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An animal experiment by a Chinese research group has shown that the holes in the kidney in diabetic rats are first formed by agAAB against the α1-AR [21]. 100 | a r c h i v e u r o m e d i c a | 2 0 1 9 | v o l .…”

Section: E T H O D S / M a T E R I A Lmentioning

confidence: 99%

Agonistic Autoantibodies, a Risk Factor in Patients with Type 2 Diabetes

Bimmler¹,

Lemke²

2019

AREM

View full text Add to dashboard Cite

In addition to insulin intolerance, patients with type 2 diabetes suffer from hypertension, renal insufficiency, retinopathy, wound healing disorders, coronary heart disease, heart attacks, strokes, and amputations. In addition to metabolic syndrome, many patients have pathological changes in macro- and microcirculation. One of the causes might be agonistic autoantibodies (agAAB), an immunological component. This specialized group of autoantibodies activates the G protein-coupled receptors similar to the way natural agonists do and triggers receptor-specific reactions in the cell (1). The pathological potential of agAAB has been described in numerous publications. The pathological processes triggered by agAAB for the ß-1-adrenoceptors (AR), AT1 AR, and α 1 AR (2,3,4,5) have been particularly well researched. Animal experiments provided valuable insights into the causality of receptor-specific autoantibodies for the development of diseases and disease-relevant symptoms. These autoantibodies can only be removed with specific antagonists at the receptor or by plasmapheresis or immunoadsorption. The agAAB do not respond to immunosuppression as classical autoantibodies do. Patients in whom agAAB was removed by extracorporeal treatment benefited from it. In patients with dilated cardiomyopathy, cardiac output improved (6,7); those with Alzheimer's disease (8) achieved stabilization of cognition. In subjects with Thromboangiitis obliterans (9), further amputations were able to be avoided after removal of the autoantibodies, and in patients with inadequate control of hypertension through pharmacological means, blood pressure was considerably reduced (10). In only a few cases did agAAB reappear. These positive treatment results for various diseases formed the basis for screening diabetics with respect to the prevalence of agonistic autoantibodies.

show abstract

Section: E T H O D S / M a T E R I A Lmentioning

confidence: 99%

Agonistic Autoantibodies, a Risk Factor in Patients with Type 2 Diabetes

Bimmler¹,

Lemke²

2019

AREM

View full text Add to dashboard Cite

show abstract

“…Alpha 1 adrenoceptor autoantibodies have been objectified in some patients with diabetic nephropathy, with deleterious effects on kidney and arterial pressure [33-34]. These autoantibodies seem to be of stimulatory nature, as their effects are contracted by the alpha 1 adrenoceptor antagonists [33-34]. This led to the suggestion that HA1A may be harmful to the kidney.…”

Section: Reviewmentioning

confidence: 99%

The Quest for Type 2 Diabetes Subgroups Identification: Literature Review for a New Subtype Proposal

Delma¹

2018

Cureus

View full text Add to dashboard Cite

Type 2 diabetes is considered typically as a heterogeneous disease that englobes the potential different subtypes with distinct pathophysiological mechanisms and/or susceptibility to complications. Some authors have succeeded in the identification of some of these subgroups, but a lot of work remains to be completed. Given the effects of the sympathetic innervation via alpha 1 adrenoceptors on diabetes target organs and the interindividual variability of this receptor sensitivity, the existence of a subtype of type 2 diabetes with hyperactivation of alpha 1 adrenoceptors (HA1A) is proposed. Based on the literature review, the potential characteristics of this phenotype and its susceptibility to certain complications have been identified in this article.

show abstract

“…Moreover, the patients may suffer from hypoglycemia, insulin resistance, weight gain, gastrointestinal adverse reactions, and liver and kidney damage [2]. Thus, developing a rational drug therapy is valuable to patients with type 2 diabetes mellitus [3]. This study aims to explore the value of invigorating qi, nourishing yin, and promoting blood circulation in ensuring clinical treatment efficacy and favorable prognosis for patients with type 2 diabetes mellitus.…”

Section: Introductionmentioning

confidence: 99%

Clinical efficacy of invigorating qi, nourishing yin, and promoting blood circulation in treatment of type 2 diabetes mellitus

Zhang¹

2018

biomedicalresearch

View full text Add to dashboard Cite

Objective: This study aims to investigate the clinical efficacy of invigorating qi, nourishing yin, and promoting blood circulation in the treatment of type 2 diabetes mellitus. Methods: Sixty-six patients with type 2 diabetes mellitus admitted to our hospital from February 2015 to January 2017 were recruited in this study. Odd-even method was used to divide the patients into two groups. Patients in the control group (n=33) were given with conventional treatment for type 2 diabetes mellitus, and those in the observation group (n=33) were administered with a conventional scheme involving invigorating qi, nourishing yin, and promoting blood circulation. The TCM syndrome efficacy and the levels of TC, FBG, and FINS were compared between the two groups. Results: Compared with the control group (72.73%), the observation group showed significantly improved TCM syndrome (96.97%) (P<0.05) and significantly increased levels of TC, FBG, and FINS (P<0.05). Conclusion: Treating patients with type 2 diabetes mellitus by invigorating qi, nourishing yin, and promoting blood circulation can ensure TCM syndrome efficacy and increase the levels of TC, FBG, and FINS levels, thereby improving the treatment outcomes.

show abstract

Doxazosin attenuates renal matrix remodeling mediated by anti-α1-adrenergic receptor antibody in a rat model of diabetes mellitus

Cited by 4 publications

References 45 publications

Agonistic Autoantibodies, a Risk Factor in Patients with Type 2 Diabetes

Agonistic Autoantibodies, a Risk Factor in Patients with Type 2 Diabetes

The Quest for Type 2 Diabetes Subgroups Identification: Literature Review for a New Subtype Proposal

Clinical efficacy of invigorating qi, nourishing yin, and promoting blood circulation in treatment of type 2 diabetes mellitus

Contact Info

Product

Resources

About